It was one year ago this month that Ashley McEvoy announced her surprising resignation as worldwide chair of J&J MedTech. She ...

Johnson & Johnson MedTech has concluded subject enrolment for the pilot phase of the OMNY-AF study of the investigational ...

Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...

Johnson & Johnson MedTech today announced the completed enrollment of the pilot phase of a clinical trial for its Omnypulse ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Oct. 10, 2024 /PRNewswire/ -- Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, announced the first phase of the VOLT™ Variable Angle Optimized Locking ...

Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...

At Advamed’s The Medtech Conference last week, the new director of the Food and Drug Administration’s device center, Michelle Tarver, shared the agency’s priorities and upcoming directives.

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating the consensus of $2.21. The pharmaceutical giant reported sales of $22.47 ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

WEST CHESTER, Penn., Oct. 10, 2024 /PRNewswire/ -- Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, announced the first phase of the VOLTTM Variable Angle ...